Does the media refer more to AGEN or LXRX?

In the previous week, Agenus had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Agenus and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.51 beat Agenus' score of -0.04 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, AGEN or OPK?

Agenus has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 3.09 $120K $1.59 4.95 OPKO Health $606.90M 1.65 -$225.68M -$0.09 N/A

Is AGEN or OPK more profitable?

Agenus has a net margin of 50.49% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% OPKO Health -12.40% -5.88% -3.83%

Does the media refer more to AGEN or OPK?

In the previous week, OPKO Health had 23 more articles in the media than Agenus. MarketBeat recorded 29 mentions for OPKO Health and 6 mentions for Agenus. OPKO Health's average media sentiment score of 0.35 beat Agenus' score of -0.04 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral OPKO Health 6 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GERN or AGEN?

Agenus has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 4.45 -$83.50M -$0.11 N/A Agenus $114.20M 3.09 $120K $1.59 4.95

Is GERN or AGEN more profitable?

Agenus has a net margin of 50.49% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Geron -35.48% -23.31% -10.08% Agenus 50.49% -31.66% 42.71%

Does the media prefer GERN or AGEN?

In the previous week, Agenus had 2 more articles in the media than Geron. MarketBeat recorded 6 mentions for Agenus and 4 mentions for Geron. Geron's average media sentiment score of 1.15 beat Agenus' score of -0.04 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher valuation & earnings, RIGL or AGEN?

Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rigel Pharmaceuticals $299.77M 2.27 $367.02M $18.72 1.97 Agenus $114.20M 3.09 $120K $1.59 4.95

Does the media prefer RIGL or AGEN?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 6 mentions for Agenus. Rigel Pharmaceuticals' average media sentiment score of 1.02 beat Agenus' score of -0.04 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is AGEN or ACHV more profitable?

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Achieve Life Sciences N/A -193.49% -111.88%

Does the media refer more to AGEN or ACHV?

In the previous week, Agenus had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 6 mentions for Agenus and 5 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.34 beat Agenus' score of -0.04 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Achieve Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Agenus (AGEN) Competitors

$7.88 +0.38 (+5.04%)

As of 12:52 PM Eastern

Compare

AGEN vs. LXRX, OPK, GERN, RIGL, and ACHV

Should you buy Agenus stock or one of its competitors? MarketBeat compares Agenus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agenus include Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry.

How does Agenus compare to Lexicon Pharmaceuticals?

Agenus (NASDAQ:AGEN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Agenus had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Agenus and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.51 beat Agenus' score of -0.04 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.5% of Agenus shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agenus has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.09	$120K	$1.59	4.95
Lexicon Pharmaceuticals	$49.80M	20.38	-$50.34M	-$0.07	N/A

Agenus has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Agenus has a net margin of 50.49% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Agenus currently has a consensus target price of $22.00, indicating a potential upside of 179.26%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 99.12%. Given Agenus' higher probable upside, research analysts clearly believe Agenus is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Agenus beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to OPKO Health?

Agenus (NASDAQ:AGEN) and OPKO Health (NASDAQ:OPK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Agenus has a net margin of 50.49% compared to OPKO Health's net margin of -12.40%. OPKO Health's return on equity of -5.88% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
OPKO Health	-12.40%	-5.88%	-3.83%

In the previous week, OPKO Health had 23 more articles in the media than Agenus. MarketBeat recorded 29 mentions for OPKO Health and 6 mentions for Agenus. OPKO Health's average media sentiment score of 0.35 beat Agenus' score of -0.04 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OPKO Health	6 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Agenus has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.09	$120K	$1.59	4.95
OPKO Health	$606.90M	1.65	-$225.68M	-$0.09	N/A

Agenus presently has a consensus price target of $22.00, indicating a potential upside of 179.26%. OPKO Health has a consensus price target of $1.55, indicating a potential upside of 15.24%. Given Agenus' stronger consensus rating and higher possible upside, analysts plainly believe Agenus is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agenus has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

61.5% of Agenus shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 6.5% of Agenus shares are held by company insiders. Comparatively, 44.7% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Agenus beats OPKO Health on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Geron?

Geron (NASDAQ:GERN) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Agenus has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.45	-$83.50M	-$0.11	N/A
Agenus	$114.20M	3.09	$120K	$1.59	4.95

Geron currently has a consensus price target of $4.00, indicating a potential upside of 213.73%. Agenus has a consensus price target of $22.00, indicating a potential upside of 179.26%. Given Geron's higher probable upside, equities research analysts plainly believe Geron is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Agenus has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Agenus had 2 more articles in the media than Geron. MarketBeat recorded 6 mentions for Agenus and 4 mentions for Geron. Geron's average media sentiment score of 1.15 beat Agenus' score of -0.04 indicating that Geron is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Agenus has a net margin of 50.49% compared to Geron's net margin of -35.48%. Geron's return on equity of -23.31% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
Agenus	50.49%	-31.66%	42.71%

73.7% of Geron shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Agenus beats Geron on 9 of the 15 factors compared between the two stocks.

How does Agenus compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Rigel Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Agenus has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Agenus. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$299.77M	2.27	$367.02M	$18.72	1.97
Agenus	$114.20M	3.09	$120K	$1.59	4.95

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 6 mentions for Agenus. Rigel Pharmaceuticals' average media sentiment score of 1.02 beat Agenus' score of -0.04 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rigel Pharmaceuticals has a net margin of 121.50% compared to Agenus' net margin of 50.49%. Rigel Pharmaceuticals' return on equity of 47.99% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Agenus	50.49%	-31.66%	42.71%

Rigel Pharmaceuticals presently has a consensus target price of $54.50, suggesting a potential upside of 48.14%. Agenus has a consensus target price of $22.00, suggesting a potential upside of 179.26%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Rigel Pharmaceuticals beats Agenus on 11 of the 16 factors compared between the two stocks.

How does Agenus compare to Achieve Life Sciences?

Agenus (NASDAQ:AGEN) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Agenus has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.09	$120K	$1.59	4.95
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Agenus has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

In the previous week, Agenus had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 6 mentions for Agenus and 5 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.34 beat Agenus' score of -0.04 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Achieve Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.5% of Agenus shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Agenus currently has a consensus target price of $22.00, indicating a potential upside of 179.26%. Achieve Life Sciences has a consensus target price of $16.00, indicating a potential upside of 155.39%. Given Agenus' higher probable upside, research analysts clearly believe Agenus is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Agenus beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$353.75M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	4.97	7.38	282.16	25.05
Price / Sales	3.09	1,220.59	576.18	79.91
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	-0.96	16.79	10.96	6.18
Net Income	$120K	-$12.56M	$3.49B	$347.61M
7 Day Performance	28.52%	-0.84%	0.45%	0.71%
1 Month Performance	125.73%	-7.59%	-4.26%	-3.75%
1 Year Performance	46.98%	49.20%	63.09%	20.17%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	3.4358 of 5 stars	$7.88 +5.0%	$22.00 +179.3%	+39.9%	$353.75M	$114.20M	4.97	440	Upcoming Earnings Analyst Upgrade Gap Up
LXRX Lexicon Pharmaceuticals	1.6553 of 5 stars	$2.23 -2.6%	$4.55 +104.0%	+115.9%	$1.02B	$49.80M	N/A	140	Upcoming Earnings
OPK OPKO Health	1.4997 of 5 stars	$1.24 +1.6%	$1.55 +25.0%	+10.9%	$921.21M	$606.90M	N/A	1,373	Earnings Report Gap Up
GERN Geron	2.5793 of 5 stars	$1.48 +4.2%	$4.00 +170.3%	+10.3%	$910.96M	$183.88M	N/A	70	Positive News Upcoming Earnings
RIGL Rigel Pharmaceuticals	4.329 of 5 stars	$37.39 +1.8%	$54.50 +45.8%	+68.0%	$679.76M	$299.77M	2.00	160	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. LXRX, OPK, GERN, RIGL, and ACHV

How does Agenus compare to Lexicon Pharmaceuticals?

Summary

How does Agenus compare to OPKO Health?

Summary

How does Agenus compare to Geron?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Summary

How does Agenus compare to Achieve Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. LXRX, OPK, GERN, RIGL, and ACHV

How does Agenus compare to Lexicon Pharmaceuticals?

Does the media refer more to AGEN or LXRX?

Do insiders & institutionals believe in AGEN or LXRX?

Which has stronger valuation & earnings, AGEN or LXRX?

Which has more volatility and risk, AGEN or LXRX?

Is AGEN or LXRX more profitable?

Do analysts prefer AGEN or LXRX?

Summary

How does Agenus compare to OPKO Health?

Is AGEN or OPK more profitable?

Does the media refer more to AGEN or OPK?

Which has better earnings and valuation, AGEN or OPK?

Do analysts prefer AGEN or OPK?

Which has more risk & volatility, AGEN or OPK?

Do insiders and institutionals believe in AGEN or OPK?

Summary

How does Agenus compare to Geron?

Which has stronger valuation and earnings, GERN or AGEN?

Do analysts recommend GERN or AGEN?

Which has more volatility & risk, GERN or AGEN?

Does the media prefer GERN or AGEN?

Is GERN or AGEN more profitable?

Do institutionals and insiders believe in GERN or AGEN?

Summary

How does Agenus compare to Rigel Pharmaceuticals?

Which has more risk and volatility, RIGL or AGEN?

Which has higher valuation & earnings, RIGL or AGEN?

Do institutionals and insiders hold more shares of RIGL or AGEN?

Does the media prefer RIGL or AGEN?

Is RIGL or AGEN more profitable?

Do analysts rate RIGL or AGEN?

Summary

How does Agenus compare to Achieve Life Sciences?

Which has higher earnings & valuation, AGEN or ACHV?

Which has more volatility & risk, AGEN or ACHV?

Does the media refer more to AGEN or ACHV?

Do insiders & institutionals hold more shares of AGEN or ACHV?

Is AGEN or ACHV more profitable?

Do analysts rate AGEN or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools